• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Torres Denice

    6/6/25 8:10:07 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Torres Denice

    (Last) (First) (Middle)
    C/O CELLDEX THERAPEUTICS, INC.
    53 FRONTAGE ROAD, SUITE 220

    (Street)
    HAMPTON NJ 08827

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    Celldex Therapeutics, Inc. [ CLDX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Sam Martin, attorney-in-fact for Denice Torres 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    9/30/2024$45.00Neutral
    Goldman
    9/27/2024Outperform → Peer Perform
    Wolfe Research
    6/18/2024$58.00Buy
    Stifel
    6/11/2024$51.00Outperform
    Wolfe Research
    More analyst ratings

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

      HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization." Ms. Torres added, "

      6/6/25 8:01:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex's first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. "In the first quarter of 2025, we presented data from our Ph

      5/8/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

      HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week (DDW) 2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 st

      5/5/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Celldex Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $64.00

      4/28/25 8:36:51 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley initiated coverage on Celldex Therapeutics with a new price target

      Morgan Stanley initiated coverage of Celldex Therapeutics with a rating of Overweight and set a new price target of $46.00

      3/20/25 7:59:39 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • UBS initiated coverage on Celldex Therapeutics with a new price target

      UBS initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $44.00

      2/13/25 8:07:26 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Torres Denice

      3 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      6/6/25 8:10:07 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Marino James J gifted 10,500 shares, decreasing direct ownership by 83% to 2,204 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/20/24 4:02:46 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    SEC Filings

    See more
    • SEC Form S-8 filed by Celldex Therapeutics Inc.

      S-8 - Celldex Therapeutics, Inc. (0000744218) (Filer)

      6/6/25 4:01:59 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

      6/6/25 8:05:21 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.

      SCHEDULE 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      5/12/25 10:44:45 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Financials

    Live finance-specific insights

    See more
    • Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

      First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz

      10/26/24 5:43:20 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

      - 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks -- Enrollment to Global Phase 3 CSU trials underway -- Company to host webcast today at 12:00 pm ET/6:00 pm CEST - HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous

      9/25/24 10:45:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

      - Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company's Phase 2 clinical trial of barzolvolim

      2/24/24 2:05:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 7:47:25 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 12:18:08 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 6:12:56 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

      HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization." Ms. Torres added, "

      6/6/25 8:01:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

      2/16/23 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

      NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin

      2/21/22 12:00:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care